NEWTOWN, PENNSYLVANIA–(Marketwired – July 5, 2016) – Helius Medical Technologies, Inc. (TSX:HSM)(OTCQB:HSDT) (“Helius” or the “Company”) is pleased to announce that the results from the Multiple Sclerosis (MS) Pilot Study, investigating PoNS™ Therapy, will be presented in London on July 6th, during the mid-year meeting for the International Neuropsychological Society (INS). The independent study took place at the Montreal Neurological Institute and Hospital and Concordia University’s PERFORM Center.
The poster, “Non-Invasive, neuromodulation combined with intensive cognitive and physical rehabilitation induces neuroplastic changes in patients with multiple sclerosis (MS)” will be presented by Dr. Gabriel Leonard, and will detail the results of PoNS™ Therapy in the 14-subject, controlled MS pilot study for which top-line results were released on Nov 2, 2015. At that time, it was announced that the active PoNS™ Therapy contributes to neuroplastic change (as measured with fMRI) and is associated with improved performance when compared to the control group.
“We are pleased to present our research in more depth to the scientific community,” said Dr. Leonard. “Our findings are very encouraging and show strong support for the underlying neuroplasticity mechanism of action hypothesis and we look forward to the results of additional studies.”
About the International Neuropsychological Society:
The International Neuropsychological Society is a multi-disciplinary, non-profit organization dedicated to enhancing communication among the scientific disciplines which contribute to the understanding of brain-behavior relationships. The Society currently has more than 4700 members throughout the world. The Society holds two meetings per year, including its Annual Meeting in North America every February and its Mid-Year Meeting outside of North America every July. (http://www.the-ins.org/)
About PoNS™ Therapy
The Portable Neuromodulation Stimulator (PoNS™) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS™ Therapy combines the use of the device with physical therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. Helius intends to file for FDA clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.
About the Montreal Neurological Institute
The Montreal Neurological Institute and Hospital – (“The Neuro”) is a world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical centers in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the world’s top minds make The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. The Montreal Neurological Institute is a McGill University research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the McGill University Health Centre.
About PERFORM Center
PERFORM is a research center, based in the Montreal community, with a distinct Concordia approach to healthy lifestyle management. It represents a significant and forward-thinking investment by the Quebec and Canadian governments as well as Concordia University in addressing the broader determinants of health.
The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (“forward-looking statements”).
All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding ongoing or planned clinical research, expected future development timelines, regulatory approvals, business initiatives and objectives and use of proceeds from financings or other business initiatives.
Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure of the Company to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s disclosure materials, including the short form prospectus filed in connection with the Offering, its Annual Report on Form 10-K filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com.
The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
Corporate Contact:
Brian Bapty
604-652-3950
[email protected]
Helius Medical Technologies, Inc.
Media Contact:
Becky Kern
914-772-2310
[email protected]
